Lexaria Bioscience (LEXX) Updates its Ongoing Human Study GLP-1-H24-4

Lexaria Bioscience Corp. (NASDAQ: LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide this progress update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia.

Enrollment of patients for all 5 Study arms has now been completed on schedule. Participation interest in the Study was extremely high, so the Study overenrolled entering a total of 24 patients per Study arm versus the original target of 20. Completion of enrollment signifies the important "last patient in" ("LPI") clinical study milestone, meaning that treatment of all patients is expected to be completed roughly twelve weeks from now, to be followed by the series of patient sample analyses, data compilation, analysis and reporting.

"Lexaria is pleased to have reached LPI enrollment completion," said John Docherty, President and Chief Scientific Officer of Lexaria Bioscience Corp. "Dosing is progressing nicely and, at this point, we are expecting the Study to complete on schedule."

You May Also Be Interested In